10647 results for 'secondary antibody HRP'

Natural killer (NK) cells are a crucial component of the innate immune system and play a significant role in eliminating tumor cells. Unlike T cells, NK cells can recognize and kill cance

B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i

Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me

Lab Methods · Flow CytometryFlow Cytometry Protocol: Two Worked Protocols, Controls and 10 Practical TipsFlow cytometry measures individual cells in a fluid stream at hundreds per second, reporting si

What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is

Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.

Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel

Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r

Cell Culture · ProtocolsPassaging Hybridoma Cells: A Detailed GuideHybridomas are productive but temperamental. They grow in suspension, are sensitive to shear and to overgrowth, and — the problem tha

Immunology · Innate LymphocytesNatural Killer Cells: Receptors, Subsets and FunctionNK cells kill without prior sensitisation and without antigen-specific receptors, using a balance of activating and

Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi

Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab

Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa